The Federal Trade Commission (FTC) on September 27, 2024 unexpectedly withdrew from a recently established Memorandum of Understanding (MOU) with ...

Ohioans must recognize the threat that vertically-integrated insurance conglomerates pose to our health and pocketbooks.

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

The lawsuit followed a scathing FTC report in July that said the "dominant ... of Georgia's independent pharmacists and the need for PBM transparency." In his veto message, Kemp voiced support ...

Boston life sciences and medical device leaders agreed that the change to a Trump administration could create a more ...

Morgan Harper is the director of policy and advocacy and Emma Freer is a senior policy analyst at the American Economic Liberties Project. “I don't know what some of the (patients) are going to ...

Calls for PBM reform focus on transparency and addressing monopolistic practices to improve drug affordability. The FTC's action underscores the need for urgent reforms to address PBMs' anti ...

FTC Chairwoman Lina Khan, with her fellow Democratic Commissioners, recently filed a suit against the leading PBMs in an effort to undermine, or even prohibit, their use of rebates to secure ...

By Andy Miller, KFF Health News. Serving as brokers among drugmakers, pharmacies, and health insurers, these health care entities have drawn scrutiny from Congress, the Federal Trade Commission, and ...

This was days after Express Scripts started the legal volleying with a federal lawsuit against the FTC, which accused the agency of making false and misleading claims about the PBM industry in a ...

“I’m proud that the FTC launched a bipartisan investigation into these shadowy middlemen, and its preliminary findings prove yet again that it’s time to bust up the PBM monopoly.” Eisai ...